	R 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	C 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	8,019	11,300	16,080	27,392	28,109	31,308	26,416	29,066	32,838	33,498	38,654	43,886	48,497	52,578	58,462
Cost of Operating Revenue	2,273	2,870	3,787	8,971	8,372	10,689	10,326	10,992	12,524	11,965	13,851	14,472	14,626	14,773	14,482
Gross Profit	5,746	8,430	12,293	18,421	19,737	20,619	16,090	18,074	20,313	21,533	24,803	29,414	33,870	37,806	43,981
Gross Margin	71.7	74.6	76.4	67.3	70.2	65.9	60.9	62.2	61.9	64.3	64.2	67.0	69.8	71.9	75.2
Total Operating Expenses	5,033	6,661	9,294	20,480	20,594	22,761	22,329	24,341	27,902	27,080	30,505	34,592	38,000	39,992	44,909
Operating Profit	2,986	4,639	6,786	6,912	7,514	8,547	4,087	4,725	4,935	6,418	8,149	9,293	10,497	12,587	13,553
Operating Margin	37.2	41.1	42.2	25.2	26.7	27.3	15.5	16.3	15.0	19.2	21.1	21.2	21.6	23.9	23.2
Financing Income/(Expense) - Net	348	229	263	-212	-408	389	31	43	124	349	795	233	924	1,251	901
Profit before Taxes	3,356	4,321	4,583	6,403	6,571	9,048	3,479	3,810	5,010	2,799	4,481	9,408	11,088	13,752	15,119
Income Taxes	313	846	702	915	914	1,212	657	601	823	515	1,076	848	1,439	2,772	3,940
Profit after Tax	2,657	2,983	3,141	4,539	4,546	6,964	2,096	2,665	3,765	2,904	3,273	8,474	9,576	10,929	11,479
PAT Margin	33.1	26.4	19.5	16.6	16.2	22.2	7.9	9.2	11.5	8.7	8.5	19.3	19.7	20.8	19.6
EPS - Basic - ex Extraordinary Items	12.83	14.43	15.18	18.88	18.89	28.98	9.80	11.11	15.69	12.10	13.64	35.32	39.91	45.55	46.20
EPS - Diluted - ex Extraordinary Items	12.83	14.43	15.17	18.87	18.88	28.98	9.79	11.11	15.69	12.10	13.64	35.32	39.91	45.55	46.20
EBIT	2,986	4,639	6,786	6,912	7,514	8,547	4,087	4,725	4,935	6,418	8,149	9,293	10,497	12,587	13,553
EBITDA	3,278	4,975	7,195	8,107	8,552	9,812	5,587	6,478	6,988	8,498	10,293	11,824	13,054	15,162	16,491
EBITDA Margin	40.9	44.0	44.7	29.6	30.4	31.3	21.1	22.3	21.3	25.4	26.6	26.9	26.9	28.8	28.2

Balance Sheet

Abridged

Understanding Balance Sheet

Sun Pharmaceutical Industries Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	R 2013 Mar 31	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	10,293	11,503	18,686	28,878	29,941	32,954	31,636	31,069	31,654	30,442	34,865	39,862	43,433	52,594	63,860
Long-Term Investments	589	1,106	788	1,187	1,692	1,050	2,760	3,721	5,003	6,222	4,949	5,068	6,502	4,758	3,856
Property Plant & Equipment - Net	2,958	3,723	4,340	8,532	8,787	10,060	10,594	10,938	11,226	11,172	11,169	11,354	11,300	11,270	12,495
Total Non-Current Assets	6,181	9,080	10,684	21,282	25,589	28,457	32,880	33,625	36,598	37,225	34,943	40,882	42,067	39,507	44,925
Total Assets	16,474	20,583	29,371	50,160	55,530	61,410	64,516	64,694	68,252	67,667	69,808	80,744	85,500	92,101	1,08,785
Total Current Liabilities	2,618	2,841	5,990	15,329	13,144	17,887	19,864	17,340	15,706	16,146	17,208	19,906	16,984	18,194	22,622
Long Term Debt	155	115	49	1,360	3,110	1,436	1,772	1,523	2,029	898	482	560	304	358	393
Total Non-Current Liabilities	458	1,117	2,935	3,938	5,319	3,093	2,454	2,632	3,421	2,041	1,533	1,522	1,390	1,420	2,283
Total Liabilities	3,077	3,958	8,925	19,267	18,463	20,980	22,318	19,971	19,128	18,187	18,742	21,428	18,374	19,615	24,905
Total Shareholders' Equity	12,236	14,990	18,525	28,041	32,982	36,640	38,314	41,409	45,264	46,463	48,011	55,995	63,667	72,218	83,570
Minority Interest	1,161	1,635	1,921	2,851	4,085	3,791	3,884	3,314	3,860	3,017	3,055	3,320	3,459	268	310
Total Equity	13,397	16,625	20,446	30,893	37,068	40,431	42,198	44,723	49,125	49,480	51,066	59,315	67,126	72,486	83,880
Total Liabilities & Equity	16,474	20,583	29,371	50,160	55,530	61,410	64,516	64,694	68,252	67,667	69,808	80,744	85,500	92,101	1,08,785

Cash Flow

Abridged

Understanding Cash Flow Statement

Sun Pharmaceutical Industries Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	C 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	3,377	3,623	3,927	5,374	6,526	7,536	4,190	5,139	5,779	3,671	7,562	10,972	11,566	15,042	14,120
Working Capital - Increase/(Decrease)	-1,005	-45	207	180	247	-409	-212	-2,696	899	2,564	1,559	-5,662	1,062	-324	-1,268
Net CF from Operating Activities	2,371	3,579	4,134	5,554	6,773	7,127	3,978	2,443	6,678	6,235	9,121	5,310	12,628	14,718	12,852
Capital Expenditures - Net	702	865	897	2,300	3,333	3,590	1,894	3,162	1,450	1,073	1,434	2,065	2,171	2,068	3,513
Net CF from Investing Activities	-1,028	-2,895	-2,565	-3,154	-4,760	-4,600	-3,918	-1,388	-2,983	327	-5,935	-8,394	-1,403	-6,176	-12,108
Dividends Paid - Cash - Total	352	440	518	310	724	243	813	480	1,379	1,559	2,159	2,519	2,898	3,614	3,934
Stock - Issuance/(Retirement) - Net	-	-	-	75	9	-1	1	0	-	-	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	-105	-75	2,275	-548	-678	1,072	588	-237	-3,123	-4,490	-2,765	4,995	-3,513	-1,165	1,761
Net Cash Flow from Financing Activities	-516	-627	530	-836	-1,587	-1,952	-1,063	-2,270	-5,443	-5,836	-5,120	2,475	-6,491	-7,682	-2,181
Free Cash Flow to Equity	1,564	2,639	5,512	2,706	2,762	4,609	2,671	-957	2,105	673	4,922	8,241	6,944	11,486	11,099
Free Operating CF net dividend	1,306	2,260	2,711	2,894	2,645	3,191	1,204	-1,250	3,756	3,506	5,468	706	7,528	8,975	5,309
Free Operating CF	1,658	2,700	3,228	3,204	3,369	3,434	2,017	-770	5,136	5,065	7,626	3,225	10,426	12,589	9,242

Business Segment Analysis

FY End:

Mar 25

Sun Pharmaceutical Industries Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 2,128.58 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 52,578.44 Cr

Assets

Pharmaceuticals (100.0%)₹ 92,100.58 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 12,586.82 Cr

Regional Segment Analysis

FY End:

Mar 25

Sun Pharmaceutical Industries Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (33.4%)₹ 17,375.58 CrUnited States of America (32.7%)₹ 17,007.66 CrEmerging markets (19.1%)₹ 9,955.97 CrRest of world (14.8%)₹ 7,702.04 Cr

Historical Segment Analysis

Track how Sun Pharmaceutical Industries Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharmaceuticals	1,170	1,495	2,086	2,202	2,129

Frequently Asked Questions

What is the revenue of Sun Pharmaceutical Industries Ltd.?

The latest trailing twelve month revenue of Sun Pharmaceutical Industries Ltd. is ₹ 58,462.00 Cr, reflecting a 1-year growth of 11.19% and a 3-year CAGR of 10.03%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Sun Pharmaceutical Industries Ltd.?

The latest trailing twelve month net profit (PAT) of Sun Pharmaceutical Industries Ltd. is ₹ 11,479.40 Cr, with a 3-year earnings CAGR of 9.36%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Sun Pharmaceutical Industries Ltd.?

The trailing twelve month EBITDA of Sun Pharmaceutical Industries Ltd. is approximately ₹ 13,553.42 Cr (based on an operating margin of 23.18%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Sun Pharmaceutical Industries Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Sun Pharmaceutical Industries Ltd. is 46.20. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Sun Pharmaceutical Industries Ltd.?

The debt-to-equity ratio of Sun Pharmaceutical Industries Ltd. stands at 0.06. The interest coverage ratio is 39.99x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Sun Pharmaceutical Industries Ltd.?

The estimated book value per share of Sun Pharmaceutical Industries Ltd. is 354.93 (derived from a P/B ratio of 5.37 and market price of ₹ 1,906.60), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Sun Pharmaceutical Industries Ltd.?

The trailing twelve month operating cash flow of Sun Pharmaceutical Industries Ltd. is ₹ 12,851.80 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Sun Pharmaceutical Industries Ltd. report consolidated or standalone financials?

Sun Pharmaceutical Industries Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.